Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study

被引：0

作者：

Carpentier, Antoine F.

Verlut, Clotilde

Ghiringhelli, Francois

Bronnimann, Charlotte

Ursu, Renata

Fumet, Jean David

Gherga, Elisabeta

Lefort, Felix

Belin, Catherine

Vernerey, Dewi

Hervieu, Alice

Laheurte, Caroline

Meurisse, Aurelia

Jacquin, Marion

Malfroy, Marine

Fagnoni-Legat, Christine

Lehmann-Che, Jacqueline

Boullerot, Laura

Cuzzubbo, Stefania

Adotevi, Olivier

机构：

[1] Hop St Louis, Paris, France

[2] Univ Hosp Besancon, Dept Neurol, F-25000 Besancon, France

[3] Ctr GF LECLERC, Early Clin Unit CLIP2 INCA, Dijon, France

[4] Hop St Andre, Bordeaux, France

[5] St Louis Hosp, AP HP, Dept Neurol, Paris, France

[6] UNICANCER, Georges Francois Leclerc Canc Ctr, Dijon, France

[7] Hop Nord Franche Comte, Dept Radiotherapy, Montbeliard, France

[8] Univ Bordeaux, Dept Med Oncol, Hop St Andre, CHU Bordeaux, Bordeaux, France

[9] Paris Cite Univ, Dept Neurol, St Louis Hosp, AP HP, Paris, France

[10] UMQVC, Besancon, France

[11] Univ Hosp Besancon, Besancon, France

[12] Ctr Georges Francois Leclerc, Dijon, France

[13] Univ Franche Comte, INSERM, EFS UFC, UMR1098,RIGHT, Besancon, France

[14] CHU Jean Minjoz Besancon, Besancon, France

[15] Univ Hosp Besancon, INSERM CIC 1431, Clin Invest Ctr, Besancon, France

[16] Univ Bourgogne Franche Comte, INSERM, EFS BFC, RIGHT,UMR1098, Besancon, France

[17] Univ Hosp Besancon, Dept Pharm, Besancon, France

[18] St Louis Hosp Paris, Paris, France

[19] Univ Hosp Besancon, Dept Med Oncol, Besancon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2005

引用

页数：1

共 50 条

[31] Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
Blakeley, Jaishri O.
Grossman, Stuart A.
Chi, Andrew S.
Mikkelsen, Tom
Rosenfeld, Myrna R.
Ahluwalia, Manmeet S.
Nabors, L. Burt
Eichler, April
Ribas, Ignacio Garcia
Desideri, Serena
Ye, Xiaobu
CLINICAL CANCER RESEARCH, 2019, 25 (01) : 73 - 79
[32] A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHWT GLIOBLASTOMA
Lukas, Rimas
Sachdev, Sean
Kumthekar, Priya
Dixit, Karan
Grimm, Sean
Gondi, Vinai
Sharp, Laura
Lezon, Ray
James, David
Lesniak, Maciej
Stupp, Roger
Wainwright, Derek
NEURO-ONCOLOGY, 2021, 23 : 51 - 52
[33] Anlotinib for patients with newly diagnosed glioblastoma with unmethylated MGMT promoter: An open-label, single-center, phase 2 clinical trial.
Yang, Kunyu
Wu, Bian
Zhang, Zhanjie
Peng, Gang
Huang, Jing
Hong, Xiaohua
Ding, Qian
Shi, Liangliang
Wang, Xuan
Zhao, Hongyang
Jiang, Xiaobing
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] MEDIAN AND 2 YEARS SURVIVAL OF NEWLY DIAGNOSED UNMETHYLATED MGMT GLIOBLASTOMA PATIENTS TREATED WITH TEMFERON IMMUNO-GENE THERAPY
Eoli, Marica
Farina, Francesca
Cuccarini, Valeria
Gentner, Bernhard
Barcella, Matteo
Anghileri, Elena
Bruzzone, Maria Grazia
Carrabba, Matteo
D'Alessandris, Quintino Giorgio
Dimeco, Francesco
Ferla, Valeria
Franzin, Alberto
Ferroli, Paolo
Gagliardi, Filippo
Legnani, Francesco
Capotondo, Alessia
Mazzoleni, Stefania
Mortini, Pietro
Olivi, Alessandro
Pallini, Roberto
Patane, Monica
Paterra, Rosina
Pollo, Bianca
Saini, Marco
Snider, Silvia
Naldini, Luigi
Russo, Carlo
Ciceri, Fabio
Finocchiaro, Gaetano
NEURO-ONCOLOGY, 2024, 26
[35] Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma
Holdhoff, Matthias
Ye, Xiaobu
Strowd, Roy E.
Nabors, Burt
Walbert, Tobias
Lieberman, Frank S.
Bagley, Stephen J.
Fiveash, John B.
Fisher, Joy D.
Desideri, Serena
Surakus, Trisha
Engelhardt, Marc
Kaindl, Thomas
Lane, Heidi A.
Litherland, Karine
Grossman, Stuart A.
Kleinberg, Lawrence R.
NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
[36] First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase
Tabatabai, G.
Freres, P.
Glas, M.
Hau, P.
von Baumgarten, L.
van den Bent, M. J.
Burger, M. C.
Seidel, C.
Herrlinger, U.
Mildenberger, I.
Neyns, B.
Schafer, H.
Wick, A.
Falk, M. H.
Chama, L. L. de Freitas
Kelemen, P. G.
Schwenke, F.
Koch, S. D.
Roche, P. Romer
Gnad-Vogt, U. S.
ANNALS OF ONCOLOGY, 2024, 35 : S406 - S406
[37] CLINICAL EFFICACY AND PK/PD RESPONSE IN A PHASE 0/2 STUDY OF NIRAPARIB PLUS RADIOTHERAPY FOR NEWLY-DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA
Sanai, Nader
Umemura, Yoshie
Margaryan, Tigran
Molloy, Jennifer
Zhang, Hualin
Knight, William
Harmon, Jocelyn
Hong, Amy
Wanebo, John
Braun, Kelly
Kennedy, William R.
Garcia, Michael
Barani, Igor
Yoo, Wonsuk
Tien, An-Chi
Tovmasyan, Artak
Mehta, Shwetal
NEURO-ONCOLOGY, 2024, 26
[38] IMPACT OF 18F-DOPA PET ON RADIOTHERAPY TARGET VOLUMES FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS; PRELIMINARY RESULTS OF A PHASE II DOSE-ESCALATION TRIAL
Brinkmann, Debra
Pafundi, Deanna
Hunt, Christopher
Lowe, Val
Yan, Elizabeth
Brown, Paul D.
Zakhary, Mark
Zhang, Yan
Seaberg, Maasa
Tseung, Hok Seum Wan Chan
Sarkaria, Jann
Laack, Nadia
NEURO-ONCOLOGY, 2018, 20 : 225 - 225
[39] PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation A Randomized Phase II Study: BrUOG 244
Elinzano, Heinrich
Glantz, Michael
Mrugala, Maciej
Kesari, Santosh
Piccioni, David E.
Kim, Lyndon
Pan, Edward
Yunus, Shakeeb
Coyle, Thomas
Timothy, Kinsella
Evans, Devon
Mantripragada, Kalyan
Boxerman, Jerrold
DiPetrillo, Thomas
Donahue, John E.
Hebda, Nicholas
Mitchell, Kristen M.
Rosati, Kayla L.
Safran, Howard
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (02): : 159 - 162
[40] Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naive recurrent glioblastoma
O'Brien, Barbara
De Groot, John
Kamiya-Matsuoka, Carlos
Weathers, Shiao-Pei
Bacha, Jeffrey
Brown, Dennis
Steino, Anne
Langlands, John
Schwartz, Richard
Kanekal, Sarath
Lopez, Lorena
Penas-Prado, Marta
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →